Financial Analysis
Since 2015, DNA Finance has been carrying out buy-side financial analyses thanks to its in-depth knowledge of the healthcare sector.
​​
Through a careful monitoring of about sixty stocks in the XBI and NBI indices (medtech, biotech and pharma), we produce analyses of listed companies in the healthcare sector with small, mid and large cap market capitalizations.
Commercial Coverage
In addition to these financial analyses for internal monitoring, DNA Finance offers commercial coverage of companies in the healthcare sector.
​
This one-off and mandated analysis involves:
- a presentation of the company and its product portfolio;
- an analysis and valuation of its products under development;
- an analysis of its financial data and its share price.
​
The offer we offer in this context is global and personalized, and it derives its added value from the diverse and complementary experiences of our Partners. Our detailed study of your company concludes with an investment recommendation.